United Therapeutics Corporation (UTHR) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, United Therapeutics Corporation (NASDAQ: UTHR) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $598.72 (+0.87% 1D, market cap $25.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, UTHR ranks #10 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UTHR carries a Roarable A- (82/100 RQD), trailing P/E of 19.1x, gross margin of 87.9%, and ROIC of 20.1%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and ROIV (Roivant Sciences Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -14.0%, cap $27.10B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
Per UTHR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001082554), United Therapeutics Corporation generated $3.18B in revenue (+10.6% YoY), $1.33B in net income, and $1.04B in free cash flow against $7.88B in total assets and $352.7M in total debt. Key quantitative strengths: Strong cash generator (88% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 22.52 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Capital intensity & 46.9% operating margin leave 5 pts on the table
Even with a 82/100 (A-) score, UTHR faces multiple-compression risk if 19.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 85.4% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($530.33) or 200D SMA ($532.79) invalidates the momentum regime and cuts Target Base ($663.38) toward Bear Floor ($490.95).
United Therapeutics Corporation (UTHR) advanced +0.87% to $598.72, trading at 94% of its 52-week range ($430.02 – $609.99). High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support.
Yahoo Finance report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
The fund bought $116.0 million of stock, lifting 390 positions and trimming none, with Okta its largest add at $1.3 million.
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on UTHR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for UTHR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, United Therapeutics Corporation (UTHR) ranks #10 by composite RQD confidence (82/100, grade A-) and #63 by equity capitalization ($25.46B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| UTHR
ACTIVE
United Therapeutics Corporation | A- | 82/100 | 19.1x | 87.9% | 20.1% | +0.87% | $25.46B | Benchmark Subject |
| INSM Insmed Incorporated | D | 44/100 | — | 79.7% | -35.0% | +0.89% | $24.37B | /insm-vs-uthr → |
| ROIV Roivant Sciences Ltd. | D | 44/100 | — | — | -14.0% | -1.63% | $27.10B | /roiv-vs-uthr → |
| ALNY Alnylam Pharmaceuticals Inc. | D+ | 55/100 | 74.2x | 81.8% | 21.3% | -5.17% | $23.28B | /alny-vs-uthr → |
| VTRS Viatris Inc. | D+ | 57/100 | — | 35.2% | -8.1% | -0.86% | $22.05B | /vtrs-vs-uthr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), United Therapeutics Corporation (UTHR) reported GAAP revenue of $3.18B (+10.6% vs. FY2024 revenue of $2.88B , and +36.7% cumulative change since FY2023) , GAAP net income of $1.33B, operating cash flow of $1.56B, and free cash flow of $1.04B (-3.7% YoY). On the balance sheet, UTHR closed FY2025 with $7.88B in total assets against $352.7M in total debt (Altman Z-Score: 22.52, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.18B | $1.33B | $1.56B | $1.04B | $7.88B | $352.7M |
| FY2024 (FY) | 2024-12-31 | $2.88B | $1.20B | $1.33B | $1.08B | $7.36B | $414.0M |
| FY2023 (FY) | 2023-12-31 | $2.33B | $984.8M | $978.0M | $873.3M | $14.00B | $3.28B |
As of 2026-11-02, United Therapeutics Corporation (NASDAQ: UTHR) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $598.72 (+0.87% 1D, market cap $25.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, UTHR ranks #10 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UTHR carries a Roarable A- (82/100 RQD), trailing P/E of 19.1x, gross margin of 87.9%, and ROIC of 20.1%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and ROIV (Roivant Sciences Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -14.0%, cap $27.10B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
Per UTHR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001082554), United Therapeutics Corporation generated $3.18B in revenue (+10.6% YoY), $1.33B in net income, and $1.04B in free cash flow against $7.88B in total assets and $352.7M in total debt. Key quantitative strengths: Strong cash generator (88% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
UTHR last traded at $598.72 (+0.87% on volume of 518,613 shares), positioning the stock +12.90% above its 50-day simple moving average ($530.33) and +12.37% above its 200-day simple moving average ($532.79). Across its 52-week range of $430.02 to $609.99, UTHR sits at the 93.7% percentile with a 14-day RSI of 66.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($562.20 to $635.24).
Why UTHR Stock advanced +0.87% Today — RQD Quant Desk Flash. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support.
Per the Roarable RQD rating, UTHR scores 82 out of 100, grade A-, labeled "Roarable Buy — Superior Risk/Reward." The five pillars are: Fundamental Cash Engine 15/20 (ROIC 20.1%; FCF yield 4.09%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 17/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 16/20 (Beta 0.95; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 22.52; Piotroski F 9/9; Debt/Equity 0.05).
For a prospective investor, the strongest pillar is the forensic balance sheet, which indicates low leverage and high reported financial-health scores. The cash-engine pillar is comparatively weaker: a 4.09% FCF yield is a valuation tradeoff, meaning the stock is priced at a level where cash generation supports a moderate rather than high yield. Insider and institutional flow pillars point to concentrated positive positioning signals, but these are short-horizon indicators and do not guarantee future returns. The macro pillar's beta of 0.95 suggests price movement roughly in line with the broader market. Upside drivers implied by the data include sustained margin strength and insider/institutional activity; valuation tradeoffs include a 19.1x trailing P/E against a 17.8x forward P/E. This section is analytical and educational, not personalized advice.
United Therapeutics Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile section. Per the Profile section, the company has a market capitalization of $25.5B. The source data does not describe specific products, customers, or revenue-generation model beyond the sector and industry classification. Gross margin of 87.9% and operating margin of 46.9% are reported in the market data section.
Real-time company headlines, analyst actions, and sector developments for United Therapeutics Corporation (UTHR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.
Welcome to the UTHR (United Therapeutics Corporation) Roar Pit. Current RQD Composite is 82/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (20.1% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on UTHR, but look at what you are paying: 19.1x trailing P/E with 87.9% gross margins. Unless United Therapeutics Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on UTHR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $593.54 (52-wk range $430.02 - $609.99), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).